Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified. - Its latest announcement, on September 25, reported preclinical Annamycin pancreatic-cancer findings presented at AACR; the company said the results came from preclinical models. - The broader market is weaker, but supplied index moves do not establish an explanation for the stock’s much larger decline. - No reliable source directly attributes the September 28 pre-market move to a specific event.